Clinical trial
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients…
NCT00398905 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00398905 |
|---|---|
| Title | Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement |
| Official title | Controlled, Double-Blind, Randomised, Dose-Ranging Study on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939 |
| Acronym | ODIXa-HIP2 |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Venous Thromboembolism |
| Intervention type | Drug |
| Interventions | Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin |
| Enrollment | 726 |
| Start date | Jan 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Nov 14, 2006 |
| Last update posted | May 8, 2009 |
| Countries | Austria, Belgium, Denmark, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Spain, Sweden and 1 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: